Dirk Hose

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. pmc Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Im Neuenheimer Feld, Heidelberg, Germany
    Haematologica 96:87-95. 2011
  2. pmc Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Blood 113:4331-40. 2009
  3. ncbi request reprint The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Srp Arh Celok Lek 139:84-9. 2011
  4. pmc Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
    Karene Mahtouk
    INSERM, U847, Montpellier, F 34197 France
    BMC Cancer 10:198. 2010
  5. ncbi request reprint Induction of angiogenesis by normal and malignant plasma cells
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Blood 114:128-43. 2009
  6. doi request reprint Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load
    Kai Neben
    Kai Neben, Anna Jauch, Jens Hillengass, Nicola Lehners, Martin Granzow, Marc S Raab, and Anthony D Ho, University of Heidelberg Thomas Hielscher, German Cancer Research Center and Anja Seckinger, Hartmut Goldschmidt, and Dirk Hose, University of Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany
    J Clin Oncol 31:4325-32. 2013
  7. doi request reprint Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients
    Leopold Sellner
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer 119:2438-46. 2013
  8. ncbi request reprint Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24
    Olaf Christensen
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    J Immunother 32:613-21. 2009
  9. doi request reprint Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
    Jens Hillengass
    Department of Hematology, Oncology, and Rheumatology, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 122:2871-5. 2008
  10. doi request reprint Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine
    Tobias Meissner
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Germany
    Clin Cancer Res 17:7240-7. 2011

Collaborators

Detail Information

Publications29

  1. pmc Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Im Neuenheimer Feld, Heidelberg, Germany
    Haematologica 96:87-95. 2011
    ..Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin polymerase inhibitors) and upcoming (e.g. aurora kinase inhibitors) compounds...
  2. pmc Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Blood 113:4331-40. 2009
    ..Using gene expression profiling, aurora kinase inhibitors as a promising therapeutic option in myeloma can be tailoredly given to patients expressing aurora-A, who in turn have an adverse prognosis...
  3. ncbi request reprint The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Srp Arh Celok Lek 139:84-9. 2011
    ..Thus, assessment of B2M and ISS-stage, iFISH, and GEP is considered extended routine diagnostics in therapy requiring multiple myeloma patients for risk assessment and, even now, to a certain extent selection of treatment...
  4. pmc Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays
    Karene Mahtouk
    INSERM, U847, Montpellier, F 34197 France
    BMC Cancer 10:198. 2010
    ..In the past few years, many myeloma growth factors (MGF) have been described in the literature. However, their relative importance and the nature of the cells producing MGF remain unidentified for many of them...
  5. ncbi request reprint Induction of angiogenesis by normal and malignant plasma cells
    Dirk Hose
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Blood 114:128-43. 2009
    ..Aberrant expression of proangiogenic and down-regulation of antiangiogenic genes by MMCs further increases the angiogenic stimulus, together leading to bone marrow angiogenesis at various degrees in all myeloma patients...
  6. doi request reprint Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load
    Kai Neben
    Kai Neben, Anna Jauch, Jens Hillengass, Nicola Lehners, Martin Granzow, Marc S Raab, and Anthony D Ho, University of Heidelberg Thomas Hielscher, German Cancer Research Center and Anja Seckinger, Hartmut Goldschmidt, and Dirk Hose, University of Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany
    J Clin Oncol 31:4325-32. 2013
    ..The aim of this study was to analyze chromosomal aberrations in terms of frequency and impact on time to progression in patients with smoldering multiple myeloma (SMM) on the background of clinical prognostic factors...
  7. doi request reprint Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients
    Leopold Sellner
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer 119:2438-46. 2013
    ..Therapeutic options for patients with recurrent multiple myeloma after autologous stem cell transplantation (ASCT) include novel agents, conventional chemotherapy, or salvage ASCT with no standard of care...
  8. ncbi request reprint Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24
    Olaf Christensen
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    J Immunother 32:613-21. 2009
    ..The current data demonstrate that Melan-A analog specific T-cells crossreact with HM1.24(aa22-30). They might be a tool for the future use in immunotherapy against MM...
  9. doi request reprint Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
    Jens Hillengass
    Department of Hematology, Oncology, and Rheumatology, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 122:2871-5. 2008
    ..Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used...
  10. doi request reprint Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine
    Tobias Meissner
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Germany
    Clin Cancer Res 17:7240-7. 2011
    ....
  11. doi request reprint Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone
    Ulrike Klein
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Cancer 117:2136-44. 2011
    ..In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)...
  12. ncbi request reprint Timing of the high-dose therapy in the area of new drugs
    Stefan Schmitt
    Department of Medicine V, University of Heidelberg, Heidelberg, Germany
    Srp Arh Celok Lek 139:90-4. 2011
    ..These results offer new perspectives in the treatment of MM with a reasonable hope of cure...
  13. doi request reprint Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)
    Tilmann Bochtler
    Amyloidosis Center, Department of Internal Medicine, Division of Hematology Oncology Rheumatology, University of Heidelberg, Heidelberg, Germany
    Blood 117:3809-15. 2011
    ....
  14. ncbi request reprint Inherited genetic susceptibility to monoclonal gammopathy of unknown significance
    Niels Weinhold
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Blood 123:2513-7; quiz 2593. 2014
    ..18; P < 10(-7)). Collectively these data are consistent with a polygenic model of disease susceptibility to MGUS. ..
  15. doi request reprint Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma
    Isabelle Herth
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Exp Hematol 41:231-40. 2013
    ..In conclusion, Thalidomide maintenance therapy has profound implications on T cell pattern and activation status, which compromise antigen specific antitumor immunity...
  16. doi request reprint Clinical and prognostic role of annexin A2 in multiple myeloma
    Anja Seckinger
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
    Blood 120:1087-94. 2012
    ..ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients...
  17. doi request reprint Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
    Kai Neben
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany
    Blood 119:940-8. 2012
    ..In conclusion, the adverse impact of del(17p13) on PFS and OS could be significantly reduced by bortezomib-based treatment, suggesting that long-term administration of bortezomib should be recommended for patients carrying del(17p13)...
  18. doi request reprint Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation
    Jens Hillengass
    German Cancer Research Center, Department of Radiology University of Heidelberg, Department of Hematology, Oncology and Rheumatology, Heidelberg, Germany
    Clin Cancer Res 15:3118-25. 2009
    ....
  19. doi request reprint NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm
    Niels Weinhold
    Medizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg, Germany
    Genes Chromosomes Cancer 49:333-41. 2010
    ..Our results indicate that the gain of chromosome 5 might play an important role in the pathogenesis of HD...
  20. doi request reprint Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
    Tilmann Bochtler
    Amyloidosis Center, Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany
    Amyloid 21:9-17. 2014
    ..Deletion 13q14 and hyperdiploidy turned out to be prognostically neutral. In conclusion, we have identified gain of 1q21 as an independent adverse prognostic factor in AL amyloidosis patients treated with standard chemotherapy...
  21. pmc Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
    Jens Hillengass
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Haematologica 97:1757-60. 2012
    ..We suggest that residual disease after high-dose chemotherapy detected by magnetic resonance imaging increases the risk of relapse. Therefore, myeloma patients with such findings after treatment might benefit from further cytoreduction...
  22. doi request reprint Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
    Mathias Witzens-Harig
    Department of Hematology Oncology, University Hospital of Heidelberg, Heidelberg, Germany
    Blood 121:4493-503. 2013
    ..These findings suggest that CEACAM-6 plays an important role in the regulation of CD8+ T-cell responses against multiple myeloma; therefore, therapeutic targeting of CEACAM-6 may be a promising strategy to improve myeloma immunotherapy...
  23. pmc The glycome of normal and malignant plasma cells
    Thomas M Moehler
    Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany Translationale Immunologie, Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany
    PLoS ONE 8:e83719. 2013
    ..The prognostically relevant glycome deviation in malignant cells invites novel strategies of therapy for multiple myeloma. ..
  24. pmc Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
    Kai Neben
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    Haematologica 95:1150-7. 2010
    ..Specific changes in interphase cells can be detected by fluorescent in situ hybridization, which overcomes the problem of the lack of dividing cells required for conventional cytogenetics...
  25. doi request reprint Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
    Tilmann Bochtler
    Department of Internal Medicine, Division of Hematology Oncology, Amyloidosis Clinic, University of Heidelberg, Heidelberg, Germany
    Blood 111:4700-5. 2008
    ..001) in both groups. Similar branching patterns were observed in an oncogenetic tree model, indicating a common mechanism of underlying karyotypic instability in these plasma cell disorders...
  26. doi request reprint The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
    Niels Weinhold
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Nat Genet 45:522-5. 2013
    ..870G>A polymorphism (P = 7.96 × 10(-11)). These results provide a model in which a constitutive genetic factor is associated with risk of a specific chromosomal translocation...
  27. doi request reprint Modeling risk stratification in human cancer
    Thierry Reme
    INSERM UM1, U1040, Institut de Recherche en Biothérapie, 34295 Montpellier, France
    Bioinformatics 29:1149-57. 2013
    ....
  28. ncbi request reprint PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics
    Christos Sachpekidis
    Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 41:1343-53. 2014
    ....
  29. pmc Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma
    Sebastian Belle
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Eur J Haematol 81:26-35. 2008
    ..The aim of this study is the identification of HLA-A2 restricted T-cell epitopes in the conserved region of the immunoglobulin-G-heavy-chain (IgGH) that can be used for immunotherapy in multiple myeloma (MM) patients...